Skip to main content
Selvita S.A. logo

Selvita S.A. — Investor Relations & Filings

Ticker · SLV ISIN · PLSLVCR00029 LEI · 25940057WQ9YP5MOQF28 WAR Professional, scientific and technical activities
Open in API
Filings indexed 1,179 across all filing types
Latest filing 2019-03-28 Audit Report / Informat…
Country PL Poland
Listing WAR SLV

About Selvita S.A.

https://selvita.com/

Selvita S.A. is a preclinical contract research organization (CRO) providing integrated services for the pharmaceutical and biotechnology sectors. The company offers comprehensive solutions across the drug discovery and development continuum, from target validation to preclinical candidate nomination. Core drug discovery capabilities include medicinal chemistry, pharmacology, DMPK, and protein sciences, supporting a wide range of modalities such as small molecules, antibodies, and protein degraders. For drug development, Selvita provides analytical support for small and large molecules, formulation, microbiology services, and manufacturing for clinical trials. The company operates under GMP and GLP quality standards, offering flexible engagement models that range from standalone studies to fully integrated programs.

Recent filings

Filing Released Lang Actions
SPRAWOZDANIE ZARZĄDU Z DZIAŁALNOŚCI SELVITA S.A.
Audit Report / Information Classification · 98% confidence The document is titled "Sprawozdanie Zarządu z działalności Selvita S.A. 2018" (Management Report on the activities of Selvita S.A. 2018) and contains a detailed Table of Contents covering financial results, operational activities, risk factors, and governance statements. Section 1, "PODSTAWOWE WIELKOŚCI EKONOMICZNO-FINANSOWE" (Basic Economic and Financial Indicators), presents comparative financial data (P&L, Balance Sheet, Cash Flow) for the full year 2018 and 2017, including EPS and book value per share. The content is comprehensive, covering the entire fiscal year, which strongly indicates an Annual Report. Although the Polish title translates to 'Management Report', in the context of mandatory regulatory filings, a comprehensive annual report containing the management's discussion and analysis (MDA) and full financial statements is typically classified as the equivalent of a 10-K (Annual Report) if it covers the full fiscal year. Given the depth and scope covering the entire year (ending 31.12.2018), it fits the definition of an Annual Report (10-K) better than an Interim Report (IR) or a standalone Audit Report (AR). FY 2018
2019-03-28 Polish
PISMO PREZESA ZARZĄDU
Audit Report / Information Classification · 95% confidence The document is a formal address to shareholders ("Drodzy Akcjonariusze Selvity!") from the CEO ("Paweł Przewięźlikowski Prezes Zarządu Selvita S.A.") summarizing the company's activities and financial performance for the year 2018 ("podsumowane działalności Grupy Kapitałowej Selvita w 2018 roku"). It discusses R&D progress (SEL24, SEL120), financing activities (share issuance in Feb 2018), growth in the service sector, personnel changes, and future outlook. This content structure—a comprehensive review of the past fiscal year's operations, strategy, and results, presented by management to shareholders—is characteristic of an Annual Report or a component thereof, often preceding or accompanying the formal 10-K filing. Given the context of a detailed operational and financial review for a full year, it strongly aligns with the scope of an Annual Report (10-K). Although it is presented as a letter/summary, the depth of the review covering the entire year suggests it is the core narrative of the annual reporting cycle, rather than just an Earnings Release (ER) or a short Fund Factsheet (FS). Since it is a detailed summary of the full year's activities, 10-K is the most appropriate classification for the underlying report type being summarized, even if this specific text is the Chairman's/CEO's letter within that report. FY 2018
2019-03-28 Polish
OŚWIADCZENIE RADY NADZORCZEJ W SPRAWIE KOMITETU AUDYTU
Audit Report / Information Classification · 95% confidence The document is titled "Oświadczenie Rady Nadzorczej Selvita S.A. dotyczące funkcjonowania Komitetu Audytu oraz wyboru firmy audytorskiej" (Statement of the Supervisory Board of Selvita S.A. regarding the functioning of the Audit Committee and the selection of the audit firm). It explicitly references Polish Ministry of Finance regulations concerning information provided by issuers of securities in connection with the publication of the annual report for 2018. The content details compliance with rules regarding the audit committee, the independence and qualifications of the audit firm (Deloitte), and policies related to auditor rotation and non-audit services. This type of formal declaration by the Supervisory Board concerning audit compliance and governance structure, often required alongside annual filings, fits best under Governance Information (CGR) or potentially Audit Report/Information (AR). Since it is a formal statement about governance structure and audit oversight rather than the audit report itself or general ESG, CGR is the most appropriate fit for detailing internal rules and board structure compliance. Given the specific focus on audit committee function and auditor selection, it is a key component of corporate governance reporting. FY 2018
2019-03-28 Polish
SPRAWOZDANIE NIEZALEŻNEGO BIEGŁEGO REWIDENTA Z BADANIA
Audit Report / Information Classification · 100% confidence The document is explicitly titled "SPRAWOZDANIE NIEZALEŻNEGO BIEGŁEGO REWIDENTA Z BADANIA" (Independent Auditor's Report on the Audit) and contains an "Opinia" (Opinion) regarding the financial statements of Selvita S.A. as of December 31, 2018. It details the scope of the audit, compliance with Polish accounting laws ('Ustawa o rachunkowości'), and key audit matters. This content perfectly matches the definition of an Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles, distinguishing it from a full Annual Report (10-K) or an Earnings Release (ER). FY 2018
2019-03-28 Polish
Dopuszczenie związku SEL120 do badań klinicznych przez FDA - Content (PL)
Regulatory Filings Classification · 92% confidence The document is a formal announcement from the Management Board ('Zarząd Selvita S.A.') in Polish. It details receiving positive feedback ('Study May Proceed' recommendation) from the FDA regarding an Investigational New Drug (IND) application (SEL120) and the subsequent decision to initiate a clinical trial. This content relates to the development and progress of a drug candidate, which is a significant corporate event impacting the company's future operations and value. It is not a full annual report (10-K), a quarterly report (IR), an earnings release (ER), or a standard regulatory filing (RNS). Since it announces a major operational milestone and decision regarding financing/development progress, it best fits the 'Capital/Financing Update' (CAP) category, as drug development milestones often trigger financing obligations or represent significant capital deployment decisions, or potentially 'Regulatory Filings' (RNS) as a general announcement. Given the specific nature of the FDA clearance leading to a clinical trial launch and a milestone payment, it is a significant corporate update. However, none of the categories perfectly capture 'Drug Development Milestone Announcement'. Comparing the options, 'CAP' (Capital/Financing Update) is plausible due to the associated $0.4M payment milestone mentioned, but 'RNS' (Regulatory Filings) is often used for specific, non-standard regulatory interactions like FDA feedback. Since this is a specific, material announcement about regulatory progress directly enabling a major business step (clinical trial), and it doesn't fit the other specific financial/governance codes, 'RNS' serves as the most appropriate general regulatory/material event disclosure category, although 'CAP' is a close second due to the financial implication. Given the context of FDA clearance, I will classify it as a general Regulatory Filing (RNS) as it is a material event disclosure that doesn't fit the other specific financial/governance/report types.
2019-03-26 Polish
Powołanie nowego Członka Zarządu Spółki - Content (PL)
Board/Management Information Classification · 99% confidence The document text is an official announcement from the Management Board (Zarząd) of Selvita S.A. regarding the appointment of Mr. Steffen Heeger to the Management Board, detailing his new responsibilities (clinical development, medical, and regulatory matters) and his professional background. This content directly relates to changes in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is short and focuses entirely on this personnel change, making MANG the most appropriate classification.
2019-03-15 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.